Table 3.
Response evaluation.
| KCVA (n = 12) | KUCC (n = 7) | OMVA (n = 5) | UNMC (n = 2) | All subjects | |
|---|---|---|---|---|---|
| Evaluable for response (n %) | 9 (75) | 5 (71.4) | 5 (100) | 1 (50) | 20 (76.9) |
| Overall survival (n %) | 0 (0) | 3 (42.9) | 1 (25) | 0 (0) | 4 (15.4) |
| Duration of survival (median, range in days)a | 197 (14, 391) | 252 (58, 385) | 258.5 (185, 390) | 201 (89, 313) | 215 (14, 391) |
| RESPONSE | |||||
| Partial response (n %) | 8 (66.7) | 5 (71.4) | 2 (40) | 1 (50) | 16 (61.5) |
| Stable disease (n %) | 0 (0) | 0 (0) | 3 (60) | 0 (0) | 3 (11.5) |
| Progressive disease (n %) | 1 (8.3) | 0 (0) | 0 (0) | 0 (0) | 1 (3.9) |
| Not evaluable (n %) | 3 (25) | 2 (28.6) | 0 (0) | 1 (50) | 6 (23.1) |
| Recurrence-free survival (median, range in days)b | 215 (66, 362) | 273 (145, 497) | – | – | 278 (147, 385) |
aPre-treatment measurement to date of death, two censored subjects.
bPre-treatment measurement to date of recurrence, three censored subjects.